Advanced search
Publication Cover
Journal of Inflammation Research Volume 17, 2024 - Issue
Submit an article Journal homepage
31
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

A Case of Punctate Psoriasis Following Treatment with Cetuximab in a Patient with Metastatic Gastric Adenocarcinoma

Juanli Fan1 Department of Dermatovenereology, Yuncheng Central Hospital, Shanxi Medical University, Yuncheng, Shanxi Province, 044000, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0005-3366-6401View further author information
ORCID Icon,
Yanmei Gong2 Department of Oncology, Yuncheng Central Hospital, Shanxi Medical University, Yuncheng, Shanxi Province, 044000, People’s Republic of ChinaView further author information
&
Gaie Yang1 Department of Dermatovenereology, Yuncheng Central Hospital, Shanxi Medical University, Yuncheng, Shanxi Province, 044000, People’s Republic of ChinaView further author information
Pages 2633-2637 | Received 26 Oct 2023, Accepted 20 Jan 2024, Published online: 28 Apr 2024

References

  • Emre S, Süngü N, Hayran Y, Demirseren DD, Aktas A, Tö D. Investigation of the PD-1/PD-L1 expression in the lesional skins of patients with psoriasis. Dermatol Pract Conc. 2023;13(2):e2023134. PMID: 37196303; PMCID: PMC10188126. doi:10.5826/dpc.1302a134
  • George A, George R. Nivolumab (PD-1 Inhibitor) induced exacerbation of psoriasis. Indian Dermatol Online J. 2020;11(2):261–262. PMID: 32477996; PMCID: PMC7247661. doi:10.4103/idoj.IDOJ_47_19
  • Hansen I, Heidrich I, Abeck F, et al. Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab. J Eur Acad Dermatol Venereol. 2023;37(5):e621–e623. PMID: 36424911. doi:10.1111/jdv.18780
  • Chang MM, Wang F, Xi N. Literature analysis of adverse drug reactions caused by Sintilimab. Chin J Drug Appl Monit. 2023;20(02):110–113.
  • He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015;5:13110. PMID: 26279307; PMCID: PMC4538573. doi:10.1038/srep13110
  • Dattilo G, Borgia F, Guarneri C, et al. Cardiovascular risk in psoriasis: current state of the art. Curr Vasc Pharmacol. 2019;17(1):85–91. PMID: 29149819. doi:10.2174/1570161115666171116163816
  • Di Lernia V, Bonamonte D, Lasagni C, et al. Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis. Pediatr Dermatol. 2016;33(5):530–535. PMID: 27443789. doi:10.1111/pde.12940
  • Di Lernia V, Guarneri C, Stingeni L, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J DermatolTreat. 2018;29(3):217–219. PMID: 28783991. doi:10.1080/09546634.2017.1364692
  • Chen M, Ma HM, Zhao RH, Guo XC, Zhang XY. A case of psoriatic drug eruption caused by PD-1 inhibitor. Chin J Lep Skin Dis. 2019;35(08):494–495.
  • Voudouri D, Nikolaou V, Laschos K, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407–412. PMID: 29096940. doi:10.1016/j.currproblcancer.2017.10.003
  • Cutroneo P, Ingrasciotta Y, Isgrò V, et al. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol Ther. 2021;34(2):e14830. PMID: 33527643. doi:10.1111/dth.14830
  • Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990–997. PMID: 30399387; PMCID: PMC6420863. doi:10.1016/j.jaad.2018.10.062

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.